Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026
Late-breaking Phase 3 disclosures for izalontamab brengitecan (iza-bren), a potential first-in-class EGFR × HER3 bispecific ADC, in EGFR-mutated non-small cell lung cancer (PANKU-Lung01) and HR+/HER2- breast cancer (PANKU-Breast01)
Late-breaking Phase 2 global data presentation for pumitamig, a PD-L1 × VEGF-A bispecific immunomodulator, from ROSETTA Lung-107 in metastatic non-small cell lung cancer
PRINCETON, N.J., October 19, 2026--Bristol Myers Squibb (NYSE: BMY) today announced it will present new data from its oncology portfolio and pipeline across a broad range of solid tumors at the European Society for Medical Oncology (ESMO) 2026 Congress to be held October 23-27 in Madrid, Spain. Across 12 oral presentations and nearly 60 disclosures, the company will highlight progress across differentiated therapeutic approaches, including:
Late-breaking global Phase 2 data for pumitamig, an investigational PD-L1 x VEGF-A bispecific immunomodulator, being jointly developed with BioNTech
Two late-breaking, Phase 3 studies of izalontamab brengitecan (iza-bren), a potential first-in-class EGFR x HER3 bispecific antibody drug conjugate (ADC), sponsored by SystImmune's parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin)
Long-term survival results evaluating Opdivo® in combination with Yervoy® in a Phase 3 late-breaking oral presentation
"BMS is advancing a new generation of oncology medicines designed to address some of the most persistent challenges faced by patients with cancer," said Cristian Massacesi, MD, executive vice president, chief medical officer and head of Development, Bristol Myers Squibb. "At ESMO 2026, we will share important data across both emerging and established modalities. From new Phase 3 results for iza-bren and new findings for pumitamig, to long-term survival data for Opdivo ® plus Yervoy ®, these results reflect the breadth of our oncology pipeline, and our focus on translating differentiated science into meaningful, durable outcomes for patients."
Key data highlights across diverse modalities and scientific approaches to be presented at the ESMO 2026 Congress:
| Abstract Title | Author | Presentation Type/# | Session Title | Session Date/Time (Local Time (Madrid) |
| Thoracic Cancer | ||||
| A Global Phase 2, Open-label Trial of Pumitamig (PD-L1 × VEGF-A bsAb) + Docetaxel Post-chemoimmunotherapy in mNSCLC: First Data from ROSETTA Lung-107 | Cho | Rapid Oral #LBA76 | Rapid Oral 2: NSCLC, Metastatic | Sunday, October 25, |
| PANKU-Lung01: Randomized Phase 3 Study of Izalontamab Brengitecan (iza-bren) in EGFR-Mutant Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After Progression on a Third Generation EGFR TKI | Zhang | Proffered Paper #LBA71 | Proffered Paper 2: NSCLC, Metastatic | Monday, October 26, |
| Phase 2 Study of Izalontamab Brengitecan (iza-bren) Plus Osimertinib in Patients with EGFR Mutant Locally Advanced or Metastatic NSCLC | Zhou | Poster #2575P | Poster Display Session | Monday, October 26, 12:00 – 12:45 PM |
| Breast/Thoracic Cancer | ||||
| Efficacy of Pumitamig (PD-L1 × VEGF-A bsAb) Plus Chemotherapy in Patients with SCLC and TNBC with Brain Metastases: Subgroup Analyses of Two Phase 2 Trials | Pavlakis | Rapid Oral #1951RO | Rapid Oral: Investigational Immunotherapy | Saturday, October 24, |
| Breast Cancer | ||||
| PANKU-Breast01: Randomized Phase 3 Study of Izalontamab Brengitecan (iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic (LA/M) Hormone Receptor-Positive/HER2- negative (HR+/HER2-) Breast Cancer (BC) | Lan | Proffered Paper #LBA50 | Proffered Paper 1: Breast Cancer, Early and Advanced Stage | Friday October 23, |
| Head and Neck Cancer | ||||
| Phase 2 Study of Izalontamab Brengitecan (iza-bren) Plus Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Ji | Rapid Oral #1542RO | Rapid Oral: Head and Neck Cancer | Sunday, October 25, |
| Gastrointestinal Cancer | ||||
| Prevalence, Prognosis, and Impact on Tumor Microenvironment of Homozygous MTAP Deletion in Advanced Solid Tumors | Rodón | Poster #4445P | Poster Display Session | Friday, October 23, |
| Final Overall Survival Results from CheckMate 8HW: Nivolumab plus Ipilimumab vs Nivolumab or Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer | Lonardi | Rapid Oral #LBA32 | Rapid Oral: Gastrointestinal Tumours, Lower Digestive | Saturday, October 24, |
| Genitourinary Cancer | ||||
| Results From a Phase 3 Trial of Neoadjuvant Chemotherapy Alone vs in Combination with Nivolumab Followed by Postsurgical Adjuvant Nivolumab in Patients with Muscle-Invasive Bladder Cancer | Necchi | Proffered Paper #4736O | Proffered Paper 1: Genitourinary Tumour, Renal and Urothelial | Friday, October 23, |
| Pan Tumor Cancer | ||||
| First Results from a Phase 2 Trial of Second-Line Pumitamig (PD-L1 × VEGF-A bsAb) Plus Chemotherapy in Unresectable Neuroendocrine Neoplasms | Xu | Proffered Paper #2393O | Proffered Paper: NETs and Endocrine Tumours | Monday, October 26, |
| When Overall Survival Is Not Enough: The Emerging Need for Context-Sensitive Endpoint Frameworks in Oncology | Cardone | Proffered Paper #3315O | Proffered Paper: Policy | Sunday, October 25, |